지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.6
- 수록면
- 138 - 151 (14page)
이용수
초록· 키워드
오류제보하기
Objectives：The purpose of this study was to compare aripiprazole versus bupropion augmentation therapy in older adult patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors(SSRIs).
Methods：This is a post-hoc analysis of a 6-week, randomized prospective open-label multi-center study in thirty older adult patients with major depressive disorder. Participants were randomized to receive aripiprazole(N=16, 2.5-10mg/day) or bupropion(N=14, 150-300mg/day) for 6 weeks. Montgomery Asberg Depression Rating Scale (MADRS), 17-item Hamilton Depression Rating scale(HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales(anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms.
Results：There was a significantly greater decrease in MADRS scores in aripiprazole group compared to bupropion group at 4(p<0.05) and 6(p<0.05) weeks. There were significantly higher response rate at week 4(p<0.05) and 6(p<0.05) and remission rate at week 6 in aripiprazole group compared to bupropion group. Individual HAM-D17 items showing significantly greater change with adjunctive aripiprazole than bupropion: insomnia, late(ES=0.81 vs. -0.24, p=0.043), psychomotor retardation(ES=1.30 vs. 0.66, p=0.024), general somatic symptoms(ES=1.24 vs. 0.00, p=0.01). On three composite scales, adjunctive aripiprazole was significantly more effective than bupropion with respect to mean change for drive(p=0.005).
Conclusion：Results of this study suggested that aripiprazole augmentation have superior efficacy in treating general and core symptoms of depression in older adult patients. Aripiprazole augmentation is associated with greater improvement in specific symptoms of depression such as psychomotor retardation, general somatic symptoms and drive.
Methods：This is a post-hoc analysis of a 6-week, randomized prospective open-label multi-center study in thirty older adult patients with major depressive disorder. Participants were randomized to receive aripiprazole(N=16, 2.5-10mg/day) or bupropion(N=14, 150-300mg/day) for 6 weeks. Montgomery Asberg Depression Rating Scale (MADRS), 17-item Hamilton Depression Rating scale(HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales(anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms.
Results：There was a significantly greater decrease in MADRS scores in aripiprazole group compared to bupropion group at 4(p<0.05) and 6(p<0.05) weeks. There were significantly higher response rate at week 4(p<0.05) and 6(p<0.05) and remission rate at week 6 in aripiprazole group compared to bupropion group. Individual HAM-D17 items showing significantly greater change with adjunctive aripiprazole than bupropion: insomnia, late(ES=0.81 vs. -0.24, p=0.043), psychomotor retardation(ES=1.30 vs. 0.66, p=0.024), general somatic symptoms(ES=1.24 vs. 0.00, p=0.01). On three composite scales, adjunctive aripiprazole was significantly more effective than bupropion with respect to mean change for drive(p=0.005).
Conclusion：Results of this study suggested that aripiprazole augmentation have superior efficacy in treating general and core symptoms of depression in older adult patients. Aripiprazole augmentation is associated with greater improvement in specific symptoms of depression such as psychomotor retardation, general somatic symptoms and drive.
목차
서론
대상 및 방법
결과
고찰
참고문헌
참고문헌 (32)
참고문헌 신청
Andrade L / 2003 / The epidemiology of major depressive episodes : results from the International Consortium of Psychiatric Epidemiology(ICPE)Surveys / Int J Methods Psychiatr Res 12:3~21
Lepine JP / 2011 / The increasing burden of depression / Neuropsychiatr Dis Treat 7:3~7
Fava M / 2003 / Background and rationale for the sequenced treatment alternatives to relieve depression(STAR*D)study / Psychiatr Clin North Am 26:457~494
Rush AJ / 2004 / Sequenced treatment alternatives to relieve depression(STAR*D) : rationale and design / Control Clin Trials 25:119~142
Trivedi MH / 2006 / Medication augmentation after the failure of SSRIs for depression / N Engl J Med 354:1243~1252
Lepine JP / 2011 / The increasing burden of depression / Neuropsychiatr Dis Treat 7:3~7
Fava M / 2003 / Background and rationale for the sequenced treatment alternatives to relieve depression(STAR*D)study / Psychiatr Clin North Am 26:457~494
Rush AJ / 2004 / Sequenced treatment alternatives to relieve depression(STAR*D) : rationale and design / Control Clin Trials 25:119~142
Trivedi MH / 2006 / Medication augmentation after the failure of SSRIs for depression / N Engl J Med 354:1243~1252
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
세로토닌 재흡수 억제제에 대한 아리피프라졸 및 부프로피온 부가요법의 우울증 세부증상에 대한 효과 비교 : 다기관, 개방표지, 무작위 연구
대한불안의학회지
2017 .01
-
여성 우울증 환자에서 Aripiprazole과 Bupropion 부가요법의 우울증상 및안전성에 대한 효과 비교 : 사후분석연구
우울조울병
2018 .01
-
The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
Clinical Psychopharmacology and Neuroscience
2019 .01
-
Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea
Clinical Psychopharmacology and Neuroscience
2017 .01
-
Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
Clinical Psychopharmacology and Neuroscience
2021 .01
-
주요우울장애 노인에 대한 Internet of Things 기반 행동 중재 : 예비연구
노인정신의학
2019 .01
-
노인성 우울증 환자와 정상 노인에서 인지기능의 비교 및 우울증 증상 변화와의 관련성 평가
노인정신의학
2018 .01
-
The potential benefits of Aripiprazole : Focus on ASD and ADHD with recent clinical study
대한소아청소년정신의학회 학술대회논문집
2019 .11
-
The Potential Benefits of Aripiprazole : Focus on ASD and ADHD with Recent Clinical Study
대한소아청소년정신의학회 학술대회논문집
2020 .11
-
Do Somatic Symptoms Predict the Severity of Depression? A Validation Study of the Korean Version of the Depression and Somatic Symptoms Scale
Journal of Korean Medical Science
2016 .01
-
Bupropion for Interferon-Alpha-Induced Depression in Patients with Hepatitis C Viral Infection: An Open-Label Study
PSYCHIATRY INVESTIGATION
2015 .01
-
Clinical Significance of the Number of Depressive Symptoms in Major Depressive Disorder: Results from the CRESCEND Study
Journal of Korean Medical Science
2016 .01
-
Network Analysis of the Symptoms of Depressive Disorders Over the Course of Therapy: Changes in Centrality Measures
PSYCHIATRY INVESTIGATION
2021 .01
-
Long-term Effects of Aripiprazole Treatment during Adolescence on Cognitive Function and Dopamine D2 Receptor Expression in Neurodevelopmentally Normal Rats
Clinical Psychopharmacology and Neuroscience
2019 .01
-
Aripiprazole, a dopamine receptor D2 (D2R) partial agonist increases the sensitization to radiotherapy in head and neck cancer cells
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
Journal of Korean Medical Science
2019 .01
-
Open channel block of Kv1.4 potassium channels by aripiprazole
The Korean Journal of Physiology & Pharmacology
2020 .01
-
The Change of Suicidal Ideation Over a 12-Week Naturalistic Treatment of Depression: Comparison Between Young People and Older Adults
PSYCHIATRY INVESTIGATION
2023 .01
-
Intramuscular Aripiprazole in the Therapy of Acute Mania for More than 24 hrs
PSYCHIATRY INVESTIGATION
2019 .01
-
Protective Behaviors Against COVID-19 and Related Factors in Korean Adults With Depressive Symptoms: Results From an Analysis of the 2020 Korean Community Health Survey
PSYCHIATRY INVESTIGATION
2024 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
고령화 패널 자료를 이용한 노인 우울증의 선행요인에 대한 탐구
송명근
,
이원석
,
문준호
관광레저연구
2021
.01
머신러닝 기법을 이용한 생활 패턴 데이터 기반 노인 우울증 탐지
이수민
,
김선영
,
조원근
외 3명
한국정보과학회 학술발표논문집
2020
.12
스마트 토이 상호작용 데이터를 활용한 노인 우울증 예측
김정훈
,
안유진
,
김지희
한국정보과학회 학술발표논문집
2020
.12
노인의 우울증에 영향을 미치는 개인수준 및 지역수준 요인
김봉정
한국웰니스학회지
2020
.11
60세 이상 여성노인의 심혈관계 위험인자와 인지장애 및 우울증과의 연관성
홍혜련
,
강현식
한국생활환경학회지
2020
.08
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2019-512-000873518